IGF-1 Medication-Driven Changes: What Raises, Lowers, and Optimizes Your Levels

Why IGF-1 Is the Key Biomarker for GH-Axis Medications

IGF-1 (insulin-like growth factor 1) is synthesized primarily in the liver in response to growth hormone (GH) signaling. Because GH pulses are transient and highly variable across the day, IGF-1 offers a stable 24-hour integrated picture of GH-axis activity, making it the preferred monitoring biomarker for any medication that touches the somatotropic axis. A single morning serum draw is sufficient.

How the GH-IGF-1 Axis Works

GH is released from the pituitary in pulses, primarily overnight. It binds hepatic GH receptors and drives IGF-1 transcription. IGF-1 then circulates bound to IGF-binding proteins (IGFBPs), predominantly IGFBP-3, which prolongs its half-life to roughly 12 to 15 hours. That long half-life is why a single fasting serum IGF-1 accurately reflects mean GH output over the prior 24 hours, unlike GH itself, which is near-undetectable between pulses.

Why Reference Ranges Are Age-Stratified

IGF-1 peaks in mid-puberty (often above 400 ng/mL), declines roughly 14 percent per decade after age 30, and reaches a nadir in the seventh and eighth decades of life. The Endocrine Society's 2011 clinical practice guideline on adult GH deficiency recommends expressing IGF-1 results as a standard deviation score (SDS) against age- and sex-matched norms rather than a single flat cut-off. An IGF-1 of 120 ng/mL is borderline low in a 35-year-old but completely normal in a 65-year-old.

What "Optimal" Means in a Longevity Context

Longevity-medicine practitioners often cite the upper-normal quartile for chronological age as a target. One frequently referenced position is an IGF-1 SDS between 0 and +1. A 2022 analysis in JAMA Network Open (N=68,028) found that both very low and very high IGF-1 levels were associated with increased all-cause mortality, supporting a "Goldilocks" interpretation rather than a simple "higher is better" premise.

Medications That Raise IGF-1

Several therapeutic categories increase IGF-1 by stimulating GH release, replacing GH directly, or providing exogenous IGF-1.

GH Secretagogues: Tesamorelin, Sermorelin, CJC-1295

Tesamorelin is a synthetic GHRH analogue. In the key phase 3 trials supporting its FDA approval for HIV-associated lipodystrophy, tesamorelin 2 mg/day raised IGF-1 from a mean of 130 ng/mL to approximately 220 ng/mL (a 69 percent increase) at 26 weeks, with placebo-corrected change of P<0.001. Off-label use in non-HIV adults at doses of 1 to 2 mg/day produces broadly similar IGF-1 responses, though individual variation is significant.

Sermorelin (GHRH 1 to 29) and the longer-acting CJC-1295 (with or without the drug affinity complex DAC modification) work by the same receptor. A randomized trial of CJC-1295 without DAC in healthy adults showed dose-dependent IGF-1 increases of 28 to 39 percent at 8 days post-injection. The DAC modification extends the half-life to approximately 8 days, sustaining IGF-1 elevation throughout a weekly dosing cycle.

GH Secretagogue Receptor Agonists: Ipamorelin and MK-677

Ipamorelin is a selective ghrelin-receptor agonist. Unlike older secretagogues such as hexarelin, it produces a GH pulse with minimal cortisol or prolactin co-secretion. Ipamorelin in animal models showed GH specificity comparable to exogenous GH itself. Human data on ipamorelin alone are limited, but combination ipamorelin/CJC-1295 protocols are widely used in peptide clinics.

MK-677 (ibutamoren) is an orally bioavailable ghrelin mimetic. A 12-month placebo-controlled trial in 65 healthy elderly adults (mean age 69) showed MK-677 25 mg/day raised IGF-1 by 39.9 percent at 12 months vs. 0.1 percent in the placebo group (P<0.001). MK-677 is not FDA-approved and remains investigational.

Recombinant Human GH (rhGH)

Recombinant GH (somatropin) raises IGF-1 in a dose-dependent, linear fashion. The Endocrine Society recommends starting adult GH replacement at 0.2 to 0.4 mg/day and titrating every 1 to 2 months to achieve an IGF-1 SDS of 0 to +2. Their 2011 guideline states: "The dose should be titrated to achieve an IGF-1 level in the normal range for age and sex, usually in the upper half of the normal range".

Recombinant IGF-1 (Mecasermin)

Mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency (Laron syndrome and related GH-insensitivity conditions). The FDA label for Increlex notes dose-dependent serum IGF-1 increases from baseline in pediatric patients receiving 0.04 to 0.12 mg/kg twice daily. It does not stimulate GH secretion; it replaces the downstream effector directly.

Testosterone and Anabolic Steroids

Testosterone raises IGF-1 modestly in hypogonadal men. A meta-analysis in the Journal of Clinical Endocrinology and Metabolism (8 RCTs, N=410) found that testosterone replacement in hypogonadal men increased IGF-1 by approximately 10 to 15 percent. Supraphysiologic doses used non-medically produce larger increases, in part because androgens upregulate hepatic GH receptors.

Medications That Lower IGF-1

Understanding IGF-1 suppression is as clinically important as knowing how to raise it. Suppression can complicate interpretation of monitoring labs when a patient starts a new medication during an optimization protocol.

Oral Estrogen vs. Transdermal Estrogen

Oral estrogen is a well-documented IGF-1 suppressor. First-pass hepatic metabolism of oral estradiol downregulates hepatic GH receptors, reducing IGF-1 synthesis independent of GH levels. A crossover trial published in JCEM comparing oral vs. Transdermal estradiol in 14 postmenopausal women showed oral estradiol reduced IGF-1 by 24 percent while transdermal estradiol produced no significant change. This distinction matters enormously for women on combined HRT and GH or peptide therapy: switching from oral to transdermal estrogen alone may raise IGF-1 by 15 to 25 percent without any change in GH-axis medications.

Glucocorticoids

High-dose glucocorticoids suppress GH pulsatility and reduce hepatic IGF-1 production. Prednisone at 20 mg/day for 4 weeks has been reported to decrease IGF-1 by up to 50 percent in adults. Lower inhaled doses produce smaller effects but may still shift IGF-1 meaningfully in patients on optimization protocols. Any patient starting or stopping chronic corticosteroids should have IGF-1 re-checked within 6 weeks.

Poorly Controlled Diabetes and Insulin Resistance

Insulin is required for normal hepatic GH-receptor expression. In states of insulin deficiency (type 1 diabetes, late type 2 diabetes) or portal insulin insufficiency, IGF-1 production falls even when GH secretion is intact or elevated. In untreated or poorly controlled type 1 diabetes, IGF-1 levels are routinely 30 to 50 percent below age-matched norms. Optimizing insulin therapy normalizes IGF-1 without any change in GH-axis medication.

Octreotide and Somatostatin Analogues

Octreotide and lanreotide are somatostatin receptor agonists used to treat acromegaly. They suppress GH pulsatility profoundly. In a Cochrane review of somatostatin analogues in acromegaly (27 studies), first-generation somatostatin analogues normalized IGF-1 in approximately 55 percent of patients. These drugs are rarely relevant in optimization contexts but are sometimes encountered in patients treated for incidentally discovered pituitary adenomas.

Monitoring IGF-1 During Medication Changes

Knowing when to check, and how to interpret the result, prevents both under-dosing and over-treatment.

Baseline Testing

Always establish a baseline IGF-1 before starting any GH-axis medication. A single morning fasting draw is sufficient. Record the lab's reference range and, if available, the SDS score for the patient's age and sex. Labs vary: Quest Diagnostics, LabCorp, and specialty endocrine labs each use slightly different immunoassays, so comparisons across labs require caution.

On-Therapy Monitoring Schedule

A practical monitoring schedule used in peptide and longevity-medicine clinics:

• Baseline: Before initiating therapy.
• 6 weeks: First on-therapy check. Useful for confirming the patient is a responder and that starting dose is in a safe range.
• 12 to 16 weeks: Dose titration decision point. If IGF-1 is below target, increase dose or frequency; if above 300 ng/mL or IGF-1 SDS above +2, reduce dose.
• Every 6 months: Steady-state maintenance check.

The Endocrine Society's GH deficiency guideline recommends monitoring IGF-1 every 1 to 2 months during dose titration, then every 6 months once stable.

IGF-1 Above the Reference Range: When to Act

An IGF-1 persistently above 300 ng/mL in adults, or an SDS above +2, should prompt dose reduction. Chronic supraphysiologic IGF-1 is associated with increased colorectal and prostate cancer risk in epidemiologic data. The Endocrine Society 2011 guideline states: "Doses that result in IGF-1 concentrations persistently above the age-specific reference range should be avoided." This applies equally to exogenous GH, GH peptides, and recombinant IGF-1.

Special Populations: Women on HRT

Women receiving combined GH peptide therapy and estrogen therapy need to have the route of estrogen delivery considered at every IGF-1 review. If a woman on oral estradiol is being titrated upward on tesamorelin because her IGF-1 remains low, switching her to transdermal estradiol first is a reasonable clinical step before increasing peptide dose. Failure to account for this interaction is a common cause of inadvertent IGF-1 oversuppression.

IGF-1 and GLP-1 Receptor Agonists: An Emerging Interaction

GLP-1 receptor agonists such as semaglutide and liraglutide are now among the most prescribed medications in the world. Their interaction with the GH-IGF-1 axis is nuanced and under-recognized.

Caloric Restriction Effect

Significant caloric restriction, which GLP-1 agonists reliably produce, independently lowers IGF-1. In the CALERIE-2 trial, 24 months of 25 percent caloric restriction in non-obese adults reduced IGF-1 by approximately 21 percent. Patients losing substantial weight on semaglutide (the STEP-1 trial reported 14.9 percent mean body weight loss at 68 weeks in N=1,961 participants) may see meaningful IGF-1 reductions driven by reduced caloric intake rather than any direct drug effect.

Direct GH-Axis Effects of GLP-1 Agonists

GLP-1 receptors are expressed in the hypothalamus and pituitary. Animal data suggest GLP-1 agonists may modestly augment GH pulsatility, but human data are limited. At present, clinicians should attribute most of the IGF-1 changes seen with GLP-1 agonists to the secondary effect of weight loss and caloric restriction, not direct GH-axis action.

Practical Implication

A patient starting semaglutide while already on a GH peptide protocol may report that their IGF-1 dropped at their next lab check. Before adjusting peptide dose upward, confirm the patient's total caloric intake and body weight trajectory. A 10 to 15 percent IGF-1 reduction attributable to caloric restriction may not warrant any change in peptide dosing.

IGF-1 as a Longevity Biomarker: What the Evidence Actually Shows

The "higher IGF-1 equals longer life" narrative is a significant oversimplification. The data support a U-shaped association.

Evidence for IGF-1 Adequacy

Adults with confirmed GH deficiency have reduced lean mass, increased visceral fat, reduced bone mineral density, and worse cardiovascular risk profiles. The Endocrine Society guideline notes that adults with GH deficiency have approximately 2-fold higher cardiovascular mortality compared to age-matched controls. Replacing GH to normalize IGF-1 improves these parameters.

Evidence Against Supraphysiologic IGF-1

Population studies consistently find that IGF-1 levels in the top quartile are associated with increased colorectal, prostate, and premenopausal breast cancer risk. A large prospective study in the Lancet (N=4,355 cases, 7,350 controls) found that men in the highest IGF-1 quartile had a relative risk of prostate cancer of 1.49 (95% CI 1.14 to 1.95) compared to the lowest quartile.

The Centenarian Paradox

Interestingly, long-lived individuals and their offspring often show reduced IGF-1 signaling. A study of Ashkenazi Jewish centenarians (N=384) published in PNAS found enrichment of loss-of-function mutations in the IGF-1 receptor gene compared to controls. This suggests that modest IGF-1 downregulation may be compatible with, or even supportive of, exceptional longevity in some genetic contexts. The clinical takeaway: optimizing IGF-1 to the normal range for age is well-supported; deliberately pushing IGF-1 to supraphysiologic levels is not.

Drug-Drug Interactions Affecting IGF-1 Monitoring Accuracy

Several medications alter IGFBP-3 levels without changing total IGF-1 production. Since most commercial IGF-1 assays measure total (bound plus free) IGF-1, and since IGF-1 is primarily IGFBP-3 bound in circulation, changes in binding protein concentration can make total IGF-1 appear falsely low or normal even when bioavailable IGF-1 is elevated, or vice versa.

Thyroid hormone excess (hyperthyroidism or over-replacement with levothyroxine) decreases IGFBP-3, which may falsely lower measured total IGF-1 despite adequate GH axis function. Estrogen (oral) reduces both IGFBP-3 and total IGF-1. In any patient with an unexpected IGF-1 result, checking IGFBP-3 alongside IGF-1 adds diagnostic clarity and costs minimally.

A study in JCEM demonstrated that IGFBP-3 measurement alongside IGF-1 improved diagnostic sensitivity for GH deficiency from 73 percent to 89 percent when combined in a multivariate model.

Practical Prescribing Framework for Medication-Driven IGF-1 Changes

The following clinical decision steps apply to any patient whose IGF-1 is outside target range during an optimization or replacement protocol.

1. Identify all active medications that could raise or lower IGF-1 (see categories above). Pay particular attention to oral estrogen, glucocorticoids, GLP-1 agonists, and thyroid medications.
2. Check timing of recent medication changes. IGF-1 takes 4 to 6 weeks to fully reflect a change in GH-axis medication. Drawing labs within 2 weeks of a dose change produces unreliable results.
3. Interpret the SDS, not just the absolute value. A 50-year-old woman with IGF-1 of 170 ng/mL may be at the 25th percentile for her age, representing a clinically low SDS, even though 170 falls inside many labs' broad adult reference range.
4. Adjust one variable at a time. If oral-to-transdermal estrogen switch and peptide dose increase are both under consideration, make one change and recheck in 6 to 8 weeks before proceeding to the second.
5. Set an upper threshold before starting therapy. Document that you will reduce dose if IGF-1 exceeds 300 ng/mL or SDS +2. Pre-specifying the stopping rule prevents anchoring bias during follow-up.

Patients on tesamorelin 2 mg/day who have not reached an IGF-1 of at least 150 ng/mL after 12 weeks should be evaluated for oral estrogen use, active glucocorticoid therapy, poorly controlled diabetes (HbA1c above 9 percent), and dietary protein insufficiency (protein intake below 0.8 g/kg/day suppresses hepatic IGF-1 synthesis independently of GH).